Premium
Induction of allogeneic tumour‐ and lymphokine‐activated lymphocytes against hepatocellular carcinoma
Author(s) -
YASUMURA SATOSHI,
HIGUCHI KIYOHIRO,
HIOKI OSAMU,
OKADA KAZUHIKO,
TSUKISHIRO TAKASHI,
TSUCHIDA TOSHIHIRO,
MIYAGIWA MIKI,
NAMBU SHUJI,
YASUYAMA TOSHIFUMI,
INOUE KYOICHI,
WATANABE AKIHARU
Publication year - 1992
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.1992.tb00950.x
Subject(s) - lymphokine activated killer cell , lymphokine , immunotherapy , cytotoxic t cell , cancer research , interleukin 2 , medicine , immunology , ctl* , cd8 , adoptive cell transfer , hepatocellular carcinoma , cytokine , biology , t cell , antigen , interleukin 21 , in vitro , immune system , biochemistry
For clinical application of adoptive immunotherapy against hepatocellular carcinoma (HCC), it is not easy to prepare tumour specific effector cells such as cytotoxic T lymphocytes (CTL). To induce potent and broad‐spectrum effectors, allogeneic cultured hepatoma cell lines (JHH‐4 and HuH‐6) were used as stimulators of peripheral blood lymphocytes (PBL) instead of autologous HCC cells. Allogeneic tumour‐ and lymphokine‐activated killer cells (ATLAK) were generated by a mixed culture of lymphocytes and allogeneic cultured tumour cells with recombinant interleukin‐2 (rIL‐2). The tumour‐killing activity of ATLAK induced by HuH‐6 was confirmed against HuH‐6 and other different HCC cell lines (JHH‐2, HuH‐7 and PLC). These activated lymphocytes were significantly more potent than lymphokine‐activated killer cells (LAK) in [ 51 Cr]‐releasing assay. The JHH‐4 stimulated ATLAK was reactive not only with JHH‐4 but also with JHH‐2. The lysis of allogeneic targets could be partially inhibited by anti‐CD8 and anti‐CD3 but not by anti‐CD4. Anti‐tumour cytotoxicity in these cultures might be mediated by CD3+CD56‐ and CD3+CD56+ effectors. These results imply that adoptive immunotherapy for HCC with ATLAK may be more feasible than that with LAK.